Large Cell Neuroendocrine Prostate Cancer: Large Is Not Small

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2024 Jan 11

PMID 38206818

Authors

Anthony V Serritella

Himisha Beltran

Tamara L Lotan

David J VanderWeele

Fatima Karzai

Ravi A Madan

Maha Hussain

Affiliations

Soon will be listed here.

Citing Articles

Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.

Haffner M, Morris M, Ding C, Sayar E, Mehra R, Robinson B Clin Cancer Res. 2024; 31(3):466-478.

PMID: 39589343 PMC: 11790385. DOI: 10.1158/1078-0432.CCR-24-2061.

Unmasking Neuroendocrine Prostate Cancer with a Machine Learning-Driven Seven-Gene Stemness Signature That Predicts Progression.

Sabater A, Sanchis P, Seniuk R, Pascual G, Anselmino N, Alonso D Int J Mol Sci. 2024; 25(21).

PMID: 39518911 PMC: 11545501. DOI: 10.3390/ijms252111356.

Unmasking Neuroendocrine Prostate Cancer with a Machine Learning-Driven 7-Gene Stemness Signature that Predicts Progression.

Sabater A, Sanchis P, Seniuk R, Pascual G, Anselmino N, Alonso D medRxiv. 2024; .

PMID: 39399052 PMC: 11469473. DOI: 10.1101/2024.09.24.24314303.

References

Aparicio A, Harzstark A, Corn P, Wen S, Araujo J, Tu S . Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013; 19(13):3621-30. PMC: 3699964. DOI: 10.1158/1078-0432.CCR-12-3791. View

Metzger A, Abel S, Wegner R, Fuhrer R, Mao S, Miller R . Patterns of care and outcomes in small cell carcinoma of the prostate: A national cancer database analysis. Prostate. 2019; 79(12):1457-1461. DOI: 10.1002/pros.23864. View

Evans A, Humphrey P, Belani J, van der Kwast T, Srigley J . Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol. 2006; 30(6):684-93. DOI: 10.1097/00000478-200606000-00003. View

Spratt D, Alshalalfa M, Fishbane N, Weiner A, Mehra R, Mahal B . Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. Clin Cancer Res. 2019; 25(22):6721-6730. PMC: 6858964. DOI: 10.1158/1078-0432.CCR-19-1587. View

Aparicio A, Tzelepi V, Araujo J, Guo C, Liang S, Troncoso P . Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate. 2011; 71(8):846-56. PMC: 3883511. DOI: 10.1002/pros.21301. View

Sleiman W, Karray O, Abi Abdallah M, Bleichner-Perez S, Kourda J, Cosma-Opris M . Large-cell neuroendocrine tumor of the prostate: a case report and review of the literature. J Med Case Rep. 2021; 15(1):254. PMC: 8103761. DOI: 10.1186/s13256-021-02830-5. View

Chen J, Yang C, Sun Y, Cao D . Expression of novel neuroendocrine marker insulinoma-associated protein 1 (INSM1) in genitourinary high-grade neuroendocrine carcinomas: An immunohistochemical study with specificity analysis and comparison to chromogranin, synaptophysin, and CD56. Pathol Res Pract. 2020; 216(6):152993. DOI: 10.1016/j.prp.2020.152993. View

Karzai F, Madan R . Deciphering the enigma of neuroendocrine prostate cancer. J Clin Invest. 2022; 132(21). PMC: 9621125. DOI: 10.1172/JCI164611. View

Tu X, Chang T, Nie L, Qiu S, Xu H, Huang Y . Large Cell Neuroendocrine Carcinoma of the Prostate: A Systematic Review and Pooled Analysis. Urol Int. 2019; 103(4):383-390. DOI: 10.1159/000499883. View

10.

Epstein J, Amin M, Beltran H, Lotan T, Mosquera J, Reuter V . Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014; 38(6):756-67. PMC: 4112087. DOI: 10.1097/PAS.0000000000000208. View

11.

Asrani K, Torres A, Woo J, Vidotto T, Tsai H, Luo J . Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer. J Pathol. 2021; 255(4):425-437. PMC: 8599638. DOI: 10.1002/path.5781. View

12.

Kaur H, Samarska I, Lu J, Faisal F, Maughan B, Murali S . Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance. Prostate. 2020; 80(12):1012-1023. PMC: 9524879. DOI: 10.1002/pros.24035. View

13.

Priemer D, Montironi R, Wang L, Williamson S, Lopez-Beltran A, Cheng L . Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification. Endocr Pathol. 2016; 27(2):123-35. DOI: 10.1007/s12022-016-9421-z. View

14.

Azad A, Jones E, Chi K . Metastatic large-cell neuroendocrine prostate carcinoma: successful treatment with androgen deprivation therapy. Clin Genitourin Cancer. 2014; 12(4):e151-3. DOI: 10.1016/j.clgc.2014.03.006. View

15.

Mosquera J, Mehra R, Regan M, Perner S, Genega E, Bueti G . Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009; 15(14):4706-11. PMC: 3717524. DOI: 10.1158/1078-0432.CCR-08-2927. View

16.

Jiang S, Kameya T, Shoji M, Dobashi Y, Shinada J, Yoshimura H . Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases. Am J Surg Pathol. 1998; 22(5):526-37. DOI: 10.1097/00000478-199805000-00002. View

17.

Aggarwal R, Huang J, Alumkal J, Zhang L, Feng F, Thomas G . Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018; 36(24):2492-2503. PMC: 6366813. DOI: 10.1200/JCO.2017.77.6880. View

18.

Conteduca V, Oromendia C, Eng K, Bareja R, Sigouros M, Molina A . Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019; 121:7-18. PMC: 6803064. DOI: 10.1016/j.ejca.2019.08.011. View

19.

Corn P, Heath E, Zurita A, Ramesh N, Xiao L, Sei E . Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019; 20(10):1432-1443. PMC: 6858999. DOI: 10.1016/S1470-2045(19)30408-5. View

20.

Acosta-Gonzalez G, Qin J, Wieczorek R, Melamed J, Deng F, Zhou M . De novo large cell neuroendocrine carcinoma of the prostate, case report and literature review. Am J Clin Exp Urol. 2015; 2(4):337-42. PMC: 4297330. View